PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:
A61N 1/39
A1
(11) International Publication Number: WO 97/38754
(43) International Publication Date: 23 October 1997 (23.10.97)

(21) International Application Number: PCT/US97/06003

(22) International Filing Date: 11 April 1997 (11.04.97)

(30) Priority Data: 60/015,361 12 April 1996 (12,04.96) US

(71) Applicant: SURVIVALINK CORPORATION [US/US]; 5420 Feltl Road, Minneapolis, MN 55343 (US).

(72) Inventors: BREWER, James, E.; 8996 Jewel Avenue South, Cottage Grove, MN 55016 (US). SWERDLOW, Charles, D.; 457 North Kenter Avenue, Los Angeles, CA 90049 (US).


(74) Agents: STANGA, Paul, W. et al.; Patterson & Keough, P.A., 1200 Rand Tower, 527 Marquette Avenue South, Minneapolis, MN 55402 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: EXTERNAL DEFIBRILLATOR HAVING LOW CAPACITANCE AND SMALL TIME CONSTANT



(57) Abstract

A method and apparatus for delivering a truncated damped sinusoidal external defibrillation waveform, which when applied through aplurality of electrodes positioned on a patient's torso will produce a desired response in the patient's cardiac cell membranes, is provided. The external defibrillator is utilized for applying a damped sinusoidal waveform having a first waveform phase, and a second waveform phase to a pair of electrodes. The external defibrillator has a first capacitive component (C1), a first inductive component (L1), a first truncating switch, and waveform control circuitry. The waveform control circuitry of the defibrillator controls the first and second truncating switches, such that the duration of the second phase waveform delivered by the second charge storage component, is greater than the duration of the first phase waveform delivered by the first charge storage component.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

		•	•				
AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
cz	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
	•	LI	Liechtenstein	SD	Sudan		
DE	Germany Denmark	LK	Sri Lanka	SE	Sweden		
DK EE	Estonia Estonia	LR	Liberia	SG	Singapore		
EE	ESIONIA	LIN	Mooria	~~			

EXTERNAL DEFIBRILLATOR HAVING LOW CAPACITANCE AND SMALL TIME CONSTANT

RELATED APPLICATIONS

This application is based on provisional patent application Serial No: 60/015,343, filed April 12, 1996 entitled METHOD OF DESIGNING EXTERNAL DEFIBRILLATOR WAVEFORMS, the contents of which are herein incorporated by reference and priority back to the April 12, 1996 filing date is hereby claimed.

10

15

20

25

30

5

FIELD OF THE INVENTION

This invention relates generally to an electrotherapy method and apparatus for delivering an electrical pulse to a patient's heart. In particular, this invention relates to a method and apparatus for creating an electrical waveform delivered by an external defibrillator based on theory and practice as described herein.

BACKGROUND OF THE INVENTION

Devices for defibrillating a heart have been known for sometime now. Implantable defibrillators are well accepted by the medical community as effective tools to combat fibrillation for an identified segment of the population. A substantial amount of research in fibrillation and the therapy of defibrillation has been done. Much of the most recent research has concentrated on understanding the effects that a defibrillation shock pulse has on fibrillation to terminate such a condition.

A monophasic waveform is defined to be a single phase, capacitive-discharge, time-truncated, waveform with exponential decay. A biphasic waveform is defined to comprise two monophasic waveforms, separated by time and of opposite polarity. The first phase is designated ϕ_1 and the second phase is designated ϕ_2 . The delivery of ϕ_1 is completed before the delivery of ϕ_2 is begun.

15

20

25

After extensive testing, it has been determined that biphasic waveforms are more efficacious than monophasic waveforms. There is a wide debate regarding the reasons for the increased efficacy of biphasic waveforms over that of a monophasic waveforms. One hypothesis holds that ϕ_1 defibrillates the heart and ϕ_2 performs a stabilizing action that keeps the heart from refibrillating.

Biphasic defibrillation waveforms are now the standard of care in clinical use for defibrillation with implantable cardioverter-defibrillators (ICDs), due to the superior performance demonstrated over that of comparable monophasic waveforms. To better understand these significantly different outcomes, ICD research has developed cardiac cell response models to defibrillation. Waveform design criteria have been derived from these first principles and have been applied to monophasic and biphasic waveforms to optimize their parameters. These principles-based design criteria have produced significant improvements over the current art of waveforms.

In a two paper set, Blair developed a model for the optimal design of a monophasic waveform when used for electrical stimulation. (1) Blair, H.A., "On the Intensity-time relations for stimulation by electric currents." I. J. Gen. Physiol. 1932; 15: 709-729. (2) Blair, H.A., "On the Intensity-time Relations for stimulation by electric currents. II. J. Gen. Physiol. 1932; 15: 731-755. Blair proposed and demonstrated that the optimal duration of a monophasic waveform is equal to the point in time at which the cell response to the stimulus is maximal. Duplicating Blair's model, Walcott extended Blair's analysis to defibrillation, where they obtained supporting experimental results. Walcott, et al., "Choosing the optimal monophasic and biphasic waveforms for ventricular defibrillation." J. Cardiovasc Electrophysiol. 1995; 6: 737-750.

Independently, Kroll developed a biphasic model for the optimal design of ϕ_2 for a biphasic defibrillation waveform. Kroll, M.W., "A minimal model of the single capacitor biphasic defibrillation waveform."

10

15

20

25

PACE 1994; 17:1782-1792. Kroll proposed that the ϕ_2 stabilizing action removed the charge deposited by ϕ_1 from those cells not stimulated by ϕ_1 . This has come to be known as "charge burping". Kroll supported his hypothesis with retrospective analysis of studies by Dixon, et al., Tang, et al., and Freese, et al. regarding single capacitor, biphasic waveform studies. Dixon, et al., "Improved defibrillation thresholds with large contoured epicardial electrodes and biphasic waveforms." Circulation 1987; 76:1176-1184; Tang, et al. "Ventricular defibrillation using biphasic waveforms: The Importance of Phasic duration." J. Am. Coll. Cardiol. 1989; 13:207-214; and Feeser, S.A., et al. "Strength-duration and probability of success curves for defibrillation with biphasic waveforms." Circulation 1990; 82: 2128-2141. Again, the Walcott group retrospectively evaluated their extension of Blair's model to ϕ_2 using the Tang and Feeser data sets. Their finding further supported Kroll's hypothesis regarding biphasic defibrillation waveforms. For further discussions on the development of these models, reference may be made to PCT publications WO 95/32020 and WO 95/09673 and to U.S. Patent No. 5,431,686.

The charge burping hypothesis can be used to develop equations that describe the time course of a cell's membrane potential during a biphasic shock pulse. At the end of ϕ_1 , those cells that were not stimulated by ϕ_1 have a residual charge due to the action of ϕ_1 on the cell. The charge burping model hypothesizes that an optimal pulse duration for ϕ_2 is that duration that removes as much of the ϕ_1 residual charge from the cell as possible. Ideally, these unstimulated cells are set back to "relative ground." The charge burping model proposed by Kroll is based on the circuit model shown in Figure 2b which is adapted from the general model of a defibrillator illustrated in Figure 2a.

The charge burping model also accounts for removing the residual cell membrane potential at the end of a ϕ_1 pulse that is independent of a ϕ_2 .

10

15

20

25

30

That is, ϕ_2 is delivered by a set of capacitors separate from the set of capacitors used to deliver ϕ_1 . This charge burping model is constructed by adding a second set of capacitors, as illustrated in Figure 3. In this figure, C_1 represents the ϕ_1 capacitor set, C_2 represents the ϕ_2 capacitor set R_H represents the resistance of the heart, and the pair C_M and R_M represent membrane series capacitance and resistance of a single cell. The node V_s represents the voltage between the electrodes, while V_M denotes the voltage across the cell membrane.

External defibrillators send electrical pulses to the patient's heart through electrodes applied to the patient's torso. External defibrillators are useful in any situation where there may be an unanticipated need to provide electrotherapy to a patient on short notice. The advantage of external defibrillators is that they may be used on a patient as needed, then subsequently moved to be used with another patient.

However, this important advantage has two fundamental limitations. First, external defibrillators do not have direct contact with the patient's heart. External defibrillators have traditionally delivered their electrotherapeutic pulses to the patient's heart from the surface of the patient's chest. This is known as the transthoracic defibrillation problem. Second, external defibrillators must be able to be used on patients having a variety of physiological differences. External defibrillators have traditionally operated according to pulse amplitude and duration parameters that can be effective in all patients. This is known as the patient variability problem.

The prior art described above effectively models implantable defibrillators, however it does not fully addressed the transthoracic defibrillation problem nor the patient variability problem. In fact, these two limitations to external defibrillators are not fully appreciated by those in the art. For example, prior art disclosures of the use of truncated exponential monophasic or biphasic shock pulses in implantable or external defibrillators have provided little guidance for the design of an

10

15

20

external defibrillator that will successfully defibrillate across a large, heterogeneous population of patients. In particular, an implantable defibrillator and an external defibrillator can deliver a shock pulse of similar form, and yet the actual implementation of the waveform delivery system is radically different.

In the past five years, new research in ICD therapy has developed and demonstrated defibrillation models that provide waveform design rules from first principles. These defibrillation models and their associated design rules for the development of defibrillation waveforms and their characteristics were first developed by Kroll and Irnich for monophasic waveforms using effective and rheobase current concepts. (1) Kroll, M.W., "A minimal model of the monophasic defibrillation pulse." PACE 1993; 15: 769. (2) Irnich, W., "Optimal truncation of defibrillation pulses." PACE 1995; 18: 673. Subsequently, Kroll, Walcott, Cleland and others developed the passive cardiac cell membrane response model for monophasic and biphasic waveforms, herein called the cell response model. (1) Kroll, M.W., "A minimal model of the single capacitor biphasic defibrillation waveform." PACE 1994; 17: 1782. (2) Walcott, G.P., Walker, R.G., Cates. A.W., Krassowska, W., Smith, W.M, Ideker RE. "Choosing the optimal monophasic and biphasic waveforms for ventricular defibrillation." J Cardiovasc Electrophysiol 1995; 6:737; and Cleland BG. "A conceptual basis for defibrillation waveforms." PACE 1996; 19:1186).

A significant increase in the understanding of waveform design has occurred and substantial improvements have been made by using these newly developed design principles. Block et al. has recently written a comprehensive survey of the new principles-based theories and their impact on optimizing internal defibrillation through improved waveforms. Block M, Breithardt G., "Optimizing defibrillation through improved waveforms." PACE 1995; 18:526.

There have not been significant developments in external defibrillation waveforms beyond the two basic monophasic waveforms: the damped sine or the truncated exponential. To date, their design for

10

15

20

25

30

transthoracic defibrillation has been based almost entirely on empirically derived data. It seems that the design of monophasic and biphasic waveforms for external defibrillation has not yet been generally influenced by the important developments in ICD research.

Recently there has been reported research on the development and validation of a biphasic truncated exponential waveform in which it was compared clinically to a damped sine waveform. For additional background, reference may be made to U.S. Patent Nos. 5,593,427, 5,601,612 and 5,607,454. See also: Gliner BE, Lyster TE, Dillon SM, Bardy GH, "Transthoracic defibrillation of swine with monophasic and biphasic waveforms." Circulation 1995; 92:1634-1643; Bardy GH, Gliner BE, Kudenchuk PJ, Poole JE, Dolack GL, Jones GK, Anderson J, Troutman C, Johnson G.; "Truncated biphasic pulses for transthoracic defibrillation." Circulation 1995; 91:1768-1774; and Bardy GH et al, "For the Transthoracic Investigators. Multicenter comparison of truncated biphasic shocks and standard damped sine wave monophasic shocks for transthoracic ventricular defibrillation." Circulation 1996; 94:2507-2514. Although the research determined a usable biphasic waveform, there was no new theoretical understanding determined for external waveform design. It appears that external waveform research may develop a "rules-of-thumb by trial and error" design approach much like that established in the early stages of theoretical ICD research. The noted limitations of the transthoracic biphasic waveform may be due in part to a lack of principlesbased design rules to determine its waveform characteristics.

Monophasic defibrillation waveforms remain the standard of care in clinical use for transthoracic defibrillation. Waveform design has not yet been influenced by the important gains made in ICD research. The limitations of present transthoracic waveforms may be due in part to a lack of application of these design principles to determine optimal waveform characteristics. To overcome these limitations, design principles and design rules based on cell response have recently been developed for external defibrillation waveforms. The transthoracic model incorporates

WO 97/38754 PCT/US97/06003

-7-

elements into a cell response model that extends it to external defibrillation.

There is a continued need for an apparatus and methodology for accurately designing an external defibrillator waveform to optimally determine waveform characteristics for any type of external defibrillator waveform.

5

10

15

20

25

30

High resistance patients, such as those patients receiving transchest external defibrillation, are not well served by low capacitor, biphasic defibrillation waveforms wherein the duration of phase one of the waveform is greater than or equal to the duration of phase two. There is a need in the industry to better serve such patients.

SUMMARY OF THE INVENTION

The present invention relates to an external defibrillation method and apparatus that addresses the limitations in the prior art. The present invention incorporates three singular practices that distinguish the practice of designing external defibrillators from the practice of designing implantable defibrillators. These practices are 1) designing multiphasic transthoracic shock pulse waveforms from principles based on cardiac electrophysiology, 2) designing multiphasic transthoracic shock pulse waveforms in which each phase of the waveform can be designed without implementation limitations placed on its charging and delivery means by such means for prior waveform phases, and 3) designing multiphasic transthoracic shock pulse waveforms to operate across a wide range of parameters determined by a large, heterogeneous population of patients.

In particular, the present invention provides for a method and apparatus for determining an optimal transchest external defibrillation waveform which, when applied through a plurality of electrodes positioned on a patient's torso will produce a desired response in the patient's cardiac cell membranes. The method includes the steps of determining and providing a quantitative description of the desired cardiac membrane response function. A quantitative model of a

15

20

30

defibrillator circuit for producing external defibrillation waveforms is then provided. Also provided is a quantitative model of a patient which includes a chest component, a heart component and a cell membrane component. Finally, a quantitative description of a transchest external defibrillation waveform that will produce the desired cardiac membrane response function is computed. The computation is made as a function of the desired cardiac membrane response function, the patient model and the defibrillator circuit model.

10 <u>BRIEF DESCRIPTION OF THE DRAWINGS</u>

Figures 1a and 1b are perspective views of an AED according to the present invention.

Figure 2a is a very simplified defibrillator model.

Figure 2b is a known monophasic defibrillation model.

Figure 3 is a known biphasic defibrillation model.

Figure 4 represents a monophasic or biphasic capacitive-discharge external defibrillation model according to the present invention.

Figure 5A represents a monophasic capacitor-inductor external defibrillator model according to the present invention.

Figure 5B represents an alternative embodiment of a biphasic capacitor-inductor external defibrillator model according to the present invention.

Figure 6A is a graph of phase-duration ratio as compared to defibrillation threshold.

Figure 6B is a graph of total duration as compared to defibrillation threshold.

Figure 7 is a graph of system time constant and capacitance as compared to both optimal duration and phase duration ratio.

DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention provides a method and apparatus for determining an optimal transchest external defibrillation waveform

15

20

25

30

which, when applied through a plurality of electrodes positioned on a patient's torso will provide a desired response in the patient's cardiac cell membrane.

The apparatus of the present invention is an automated external defibrillator (AED) illustrated in Figures 1a and 1b. Figure 1a illustrates an AED 10, including a plastic case 12 with a carrying handle 14. A lid 16 is provided which covers an electrode compartment 18. An electrode connector 20, a speaker 22 and a diagnostic panel (not shown) are located on case 12 within electrode compartment 18. Figure 1b illustrates AED 10 having a pair of electrodes 24 connected thereto. Electrodes 24 can be preconnected to connector 20 and stored in compartment 18.

The operation of AED 10 is described briefly below. A rescue mode of AED 10 is initiated when lid 16 is opened to access electrodes 24. The opening of lid 16 is detected by AED 10 to effectively turn on the device. AED 10 then quickly runs a short test routine. After electrodes 24 have been placed on the patient, AED 10 senses patient specific parameters, such as the impedance of the patient. The patient specific parameters are then utilized in the design of optimal waveforms as will be described below.

If a shockable condition is detected through electrodes 24, a plurality of capacitors inside of AED 10 are charged from an energy source, typically a detachable battery pack. Based upon the patient specific parameters sensed, the duration and other characteristics of a discharge waveform are then calculated. The energy stored in AED 10 is then discharged to the patient through electrodes 24.

For a more detailed description of the physical structure of AED 10 or the process involved in sensing, charging, shocking and testing, reference should be made to applicants co-pending Application Serial No. 08/512,441, filed August 8, 1995 entitled AUTOMATED EXTERNAL DEFIBRILLATOR WITH SELF-TEST SYSTEM which is assigned to the assignee of the present invention, the disclosure of which is herein incorporated by reference.

10

15

20

25

30

In the present invention it is not assumed that both phases of a biphasic waveform are delivered using the same set of capacitors or that both phases of a biphasic waveform are delivered using the capacitor set in the same electrical configuration, although such an embodiment is considered within the spirit and scope of the present invention.

Transthoracic defibrillation is generally performed by placing electrodes on the apex and anterior positions of the chest wall. With this electrode arrangement, nearly all current passing through the heart is conducted by the lungs and the equipotential surfaces pass through the myocardium normal to the electrode axis. The present invention uses the transthoracic charge burping model to develop design equations that describe the time course of a cell's membrane potential during a transthoracic biphasic shock pulse. These equations are then used to create equations that describe the design of monophasic and biphasic shock pulses for transchest defibrillation to optimize the design of ϕ_1 for defibrillating and the design of ϕ_2 for stabilizing. These optimizing shock pulse design equations are called design rules.

According to the present invention, the main series pathway for current is to pass through the chest wall, the lungs, and the heart. Additionally, there are two important shunting pathways in parallel with the current pathway through the heart. These shunting pathways must be taken into consideration. The lungs shunt current around the heart through a parallel pathway. The second shunting pathway is provided by the thoracic cage. The resistivity of the thoracic cage and the skeletal muscle structure is low when compared to lungs. The high resistivity of the lungs and the shunting pathways are characterizing elements of external defibrillation that distinguish the art from intracardiac defibrillation and implantable defibrillation technologies.

Therefore, in the transthoracic defibrillation model of the present invention illustrated in Figure 4, there are several resistances in addition to those discussed for the charge burping model above. R_S represents the

WO 97/38754 PCT/US97/06003

5

10

15

20

25

resistance of the defibrillation system, including the resistance of the defibrillation electrodes. R_{CW} and R_{LS} represent the resistances of the chest wall and the lungs, respectively, in series with resistance of the heart, R_{H} . R_{TC} and R_{LP} represent the resistances of the thoracic cage and the lungs, respectively, in parallel with the resistance of the heart.

The design rules for external defibrillation waveforms are determined in three steps. In the first step, the transchest forcing function is determined. The transchest forcing function is the name that is given to the voltage that is applied across each cardiac cell during an external defibrillation shock. In the second step, the design equations for $\boldsymbol{\varphi}_1$ of a shock pulse are determined. The design equations are the equations describing the cell's response to the ϕ_1 transchest forcing function, the equation describing the optimal ϕ_1 pulse duration, and the equation describing the optimal ϕ_1 capacitor. Therefore, step two relates the cell response to the action of a monophasic shock pulse or the first phase of a biphasic shock pulse. This relation is used to determine the optimal design rules and thereby design parameters for the implementation of this phase in an external defibrillator. It will be clear to those in the art that step two is not restricted to capacitor discharge shock pulses and their associated transchest forcing function. Another common implementation of an external defibrillator incorporates a damped sine wave for a shock pulse and can be either a monophasic or biphasic waveform. This type of external defibrillator is modeled by the circuit shown in Figure 5. In the third step, the design equations for ϕ_2 of a shock pulse are determined. The design equations are the equations describing the cell's response to the φ_2 transchest forcing function, the equation describing the optimal φ_2 pulse duration and the equation describing the optimal ϕ_2 capacitor. These design equations are employed to determine the optimal design rules and thereby design parameters of ϕ_2 of a biphasic shock pulse with respect to

how the cell responds to the shock pulse. An important element of this invention is to provide shock pulse waveforms that are designed from a cardiac cell response model developed from first principles and that correctly determines the effects of the chest and its components on the ability of a shock pulse to defibrillate.

The transchest forcing function is determined by solving for the voltage found at node V_3 in Figure 4. The transchest forcing function is derived by solving for V_3 using the following three nodal equations:

(1)
$$\frac{V_1 - V_S}{R_S} + \frac{V_1}{R_{TC}} + \frac{V_1 - V_2}{R_{CW}} = 0,$$

10 (2)
$$\frac{V_2 - V_1}{R_{CW}} + \frac{V_2}{R_{LP}} + \frac{V_2 - V_3}{R_{LS}} = 0, \text{ and}$$

(3)
$$\frac{V_3 - V_2}{R_{LS}} + \frac{V_3}{R_H} + \frac{V_3 - V_M}{R_M} = 0.$$

Equation 1 can be rewritten as

(4A)
$$V_1(\frac{1}{R_S} + \frac{1}{R_{TC}} + \frac{1}{R_{CW}}) = \frac{V_S}{R_S} + \frac{V_2}{R_{CW}}.$$

$$V_{1} = \frac{V_{S}}{R_{S}\Omega_{1}} + \frac{V_{2}}{R_{CW}\Omega_{1}}, \text{ where}$$

$$\Omega_{1} = \frac{1}{R_{S}} + \frac{1}{R_{TC}} + \frac{1}{R_{CW}}.$$

Rewriting equation 2, we have

(4C)
$$V_2(\frac{1}{R_{CW}} + \frac{1}{R_{LP}} + \frac{1}{R_{LS}}) = \frac{V_1}{R_{CW}} + \frac{V_3}{R_{LS}}.$$

By substituting equation 4B for V_1 into equation 4C, we can solve for V_2 as an expression of V_S and V_3 :

$$V_{2} = \frac{V_{S}}{R_{S}R_{CW}\Omega_{1}\Omega_{2}\Omega_{22}} + \frac{V_{3}}{R_{LS}\Omega_{2}\Omega_{22}}, \text{ where}$$

$$\Omega_{2} = \frac{1}{R_{LS}} + \frac{1}{R_{LP}} + \frac{1}{R_{CW}}, \text{ and}$$

$$\Omega_{22} = 1 - \frac{1}{R_{CW}\Omega_{1}\Omega_{2}}.$$

Now solving for V_3 as an expression of V_S and V_M , equation 3 may be rearranged as

10 (6)
$$V_3(\frac{1}{R_{LS}} + \frac{1}{R_H} + \frac{1}{R_M}) = \frac{V_2}{R_{LS}} + \frac{V_M}{R_M}$$

so that

(7)
$$V_{3} = \frac{V_{2}}{R_{LS}\Omega_{3}} + \frac{V_{M}}{R_{M}\Omega_{3}}$$
where $\Omega_{3} = \frac{1}{R_{LS}} + \frac{1}{R_{H}} + \frac{1}{R_{M}}$.

Substituting equation 5 for V_2 into equation 7, we can solve for V_3 as an expression of V_S and V_M :

5 (8)
$$V_3 = \frac{V_S}{R_S R_{CW} R_{LS} \Omega_1 \Omega_2 \Omega_{22} \Omega_3 \Omega_{33}} + \frac{V_M}{R_M \Omega_3 \Omega_{33}}$$

where

(9)
$$\Omega_{33} = 1 - \frac{1}{(R_{LS}^2 \Omega_2 \Omega_{22}^2 \Omega_3)}$$

From equation 8 we define Ω_{M} to be:

$$\Omega_{M} = R_{M} \Omega_{3} \Omega_{33} = R_{M} \Omega_{3} (1 - \frac{1}{(R_{LS}^{2} \Omega_{2} \Omega_{22} \Omega_{3})})$$

$$\Omega_{M} = R_{M} (\Omega_{3} - \frac{1}{R_{LS}^{2} (\Omega_{2} - \frac{1}{R_{CW}^{2} \Omega_{1}})})$$

10 From equation 8 we also define Ω_S to be:

WO 97/38754 PCT/US97/06003

$$\Omega_{S} = R_{S} R_{CW} R_{LS} \Omega_{1} \Omega_{2} \Omega_{3} \Omega_{22} \Omega_{33}$$

(12)

$$\Omega_{S} = R_{S} R_{CW} R_{LS} \Omega_{1} \Omega_{2} (1 - \frac{1}{(R_{CW}^{2} \Omega_{1} \Omega_{2})}) \Omega_{3} (1 - \frac{1}{(R_{LS}^{2} \Omega_{2} \Omega_{22} \Omega_{3})})$$

(13)

10

15

$$^{5} \quad \Omega_{S} = R_{S} R_{CW} R_{LS} (\Omega_{1} \Omega_{2} - \frac{1}{R_{CW}^{2}}) (\Omega_{3} - \frac{1}{R_{LS}^{2} (\Omega_{2} - \frac{1}{R_{CW}^{2} \Omega_{1}})})$$

(14) so that
$$V_3 = \frac{V_S}{\Omega_S} + \frac{V_M}{\Omega_M}$$

is the general transchest transfer function as shown in Figure 4 or Figures 5A and 5B. Equation 14 incapsulates the transchest elements and their association between the forcing function V_S (which models a defibrillation circuit and the shock pulse) and the cell membrane voltage V_M . Therefore, this completes the first step.

The variable V_S may now be replaced with a more specific description of the defibrillation circuitry that implements a shock pulse. For a first example, a monophasic time-truncated, capacitive-discharge circuit may be represented by $V_S = V_1 e^{-t/\tau_1}$, where V_1 is the leading-edge voltage for the shock pulse and $\tau_1 = RC_1$, with R determined below.

As shown in Figures 5A and 5B, a second example would be a monophasic damped sine wave circuit, represented by

(14B)
$$V_S = V_1 \left(\frac{\tau_{C1}}{\tau_{C1} - \tau_{L1}} \right) \left(e^{-t/\tau_{C1}} - e^{-t/\tau_{L1}} \right)$$

where V_1 is the voltage on the charged capacitor C_1 , $\tau_{C1} = RC_1$ and $\tau_{L1} = L_1/R$. Every step illustrated below may be performed with this and other similar transchest forcing functions which represent defibrillator circuitry.

To proceed with step two, from Figure 4, nodal analysis provides an equation for V_{M} :

(15)
$$C_{M} \frac{dV_{M}}{dt} + \frac{V_{M} - V_{3}}{R_{M}} = 0.$$

Rearranging equation 15, we have

(16)
$$C_{M} \frac{dV_{M}}{dt} + \frac{V_{M}}{R_{M}} = \frac{V_{3}}{R_{M}}.$$

10

Next, substituting equation 14 as an expression for V_3 into equation 16, the cell membrane response is now calculated as follows:

(17)
$$C_{M} \frac{dV_{M}}{dt} + \frac{V_{M}}{R_{M}} = \frac{1}{R_{M}} (\frac{V_{S}}{\Omega_{S}} + \frac{V_{M}}{\Omega_{M}})$$

15

$$C_{M} \frac{dV_{M}}{dt} + \frac{V_{M}}{R_{M}} - \frac{V_{M}}{R_{M}\Omega_{M}} = \frac{V_{S}}{R_{M}\Omega_{S}}$$

(18)

$$C_{M} \frac{dV_{M}}{dt} + \frac{V_{M}}{R_{M}} (1 - \frac{1}{\Omega_{M}}) = \frac{V_{S}}{R_{M} \Omega_{S}}$$

10

20

 t/τ_2 ;

Dividing through by C_M , and setting $\tau_M = R_M \, C_M$, then equation 18 becomes

(19)
$$\frac{dV_{M}}{dt} + \frac{V_{M}}{\tau_{M}} (1 - \frac{1}{\Omega_{M}}) = \frac{V_{S}}{\tau_{M}} (\frac{1}{\Omega_{S}}).$$

Equation 19 is a general ordinary differential equation (ODE) that models the effects of any general forcing function V_S that represents a phase of a shock pulse waveform applied across the chest. The general ODE equation 19 models the effects of a general shock pulse phase V_S on the myocardium, determining cardiac cell response to such a shock pulse phase.

In the equations given below:

 C_1 equals the capacitance of the first capacitor bank and $V_S = V_1 e^{-t/\tau_1}$; C_2 equals the capacitance of the second capacitor bank and $V_S = V_2 e^{-t/\tau_1}$

 $R = R_S + R_B$, where $R_S = System$ impedance (device and electrodes); $R_B = body$ impedance (thoracic cage, chest wall, lungs (series, parallel), heart).

To determine body impedance, R_B , we see that the series combination of R_H and R_{LS} yields $R_H + R_{LS}$. (Figure 4). The parallel combination of $R_H + R_{LS}$ and R_{LP} yields:

(20)
$$\frac{R_{LP}(R_{LS} + R_{H})}{R_{LP} + R_{LS} + R_{H}}.$$

The series combination of equation 20 and $R_{\text{CW}}\,$ yields:

(21)
$$R_{CW}^{+} = \frac{R_{LP}(R_{LS}^{+} R_{H})}{(R_{LP}^{+} R_{LS}^{+} R_{H})}$$
.

The parallel combination of equation 21 and R_{TC} yields:

(22)
$$R_{B} = \left[\frac{R_{TC}[R_{CW}^{+} \frac{R_{LP}(R_{LS}^{+} R_{H}^{+})}{(R_{LP}^{+} R_{LS}^{+} R_{H}^{+})}}{R_{TC}^{+} R_{CW}^{+} \frac{R_{LP}(R_{LS}^{+} R_{H}^{+})}{(R_{LP}^{+} R_{LS}^{+} R_{H}^{+})}} \right]$$

5 where R_B is the impedance of the body for this model.

The discharge of a single capacitor is modeled by $V_S = V_1 e^{-t/\tau_1}$ for an initial C_1 capacitor voltage of V_1 . Placing V_S into equation 19 gives:

(23)
$$\frac{dV_{M}}{dt} + \frac{V_{M}}{\tau_{M}} (1 - \frac{1}{\Omega_{M}}) = \frac{V_{1}e^{-t/\tau_{1}}}{\tau_{M}\Omega_{S}}$$

where $\tau_M = R_M C_M$ represents the time constant of the myocardial cell in the circuit model, and τ_1 , which equals $R_S C_1$, represents the time constant of ϕ_1 . Such a standard linear ODE as equation 23 has the form $\frac{dy}{dx} + P(X) \ Y = Q(x)$. These linear ODEs have an integration factor that equals e^{Jpdx} . The general solution to such equations is:

15
$$Y=e^{-\int p dx} \left[\int e^{\int p dx} Q dx + c \right].$$

The ODE in equation 23 models the effects of each phase of a time-truncated, capacitor-discharged shock pulse waveform. Equation 23 is a first-order linear ODE, and may be solved using the method of integration factors, to get:

5

10

(24)

$$V_{M1}^{(t)} = ke^{-(t/\tau_M)(1-\frac{1}{\Omega_M})} + (\frac{V_1}{\Omega_S})(\frac{\tau_1}{\tau_1(1-\frac{1}{\Omega_M})-\tau_M})e^{-t/\tau_1}$$

Equation 24 is an expression of cell membrane potential during ϕ_1 of a shock pulse. To determine the constant of integration k, the initial value of V_{M1} is assumed to be $V_{M1}(0) = V_G$ ("cell ground"). Applying this initial condition to equation 24, k is found to be

(25)
$$k = V_G - (\frac{V_o}{\Omega_S}) (\frac{\tau_1}{\tau_1 (1 - \frac{1}{\Omega_M}) - \tau_M}).$$

Assuming $\tau_1 = RC_1$, where $R = R_S + R_B$, then the solution to the initial-value problem for ϕ_1 is:

(26)

$$V_{M1}(t) = V_{G}e^{-(t/\tau_{M}^{\chi 1} - \frac{1}{\Omega_{M}})} + (\frac{V_{1}}{\Omega_{S}})(\frac{\tau_{1}}{\tau_{1}(1 - \frac{1}{\Omega_{M}}) - \tau_{M}})(e^{-t/\tau_{1}} - e^{-(t/\tau_{M}^{\chi 1} - \frac{1}{\Omega_{M}})})$$

Equation 26 describes the residual voltage found on a cell at the end of ϕ_1 .

Assuming $V_G = 0$ and $V_1 = 1$, the solution for cell response to an external shock pulse is

5 (27)

$$V_{M1}(t) = (\frac{1}{\Omega_s})(\frac{\tau_1}{\tau_1(1-\frac{1}{\Omega_M})-\tau_M}) (e^{-\frac{t}{\tau_1}} - e^{-(\frac{t}{\tau_M})(1-\frac{1}{\Omega_M})}).$$

We may now determine optimal durations for ϕ_1 according to criteria for desired cell response. One such design role or criterion is that the ϕ_1 duration is equal to the time required for the external defibrillator shock pulse to bring the cell response to its maximum possible level. To determine this duration, equation 27 is differentiated and the resulting equation 27B is set to zero. Equation 27B is then solved for the time t, which represents shock pulse duration required to maximize cardiac cell response.

15

10

(27B)
$$(\frac{AB}{\tau_{M}}) e^{-Bt/\tau_{M}} - (\frac{A}{\tau_{1}}) e^{-t/\tau_{1}} = 0,$$

$$where A = (\frac{1}{\Omega_{S}}) (\frac{\tau_{1}}{\tau_{1}(1 - \frac{1}{\Omega_{M}}) - \tau_{M}})$$

$$and B = 1 - \frac{1}{\Omega_{M}}.$$

15

Solving for t, the optimal duration $d\varphi_1$ for a monophasic shock pulse or φ_1 of a biphasic shock pulse is found to be

(27C)
$$d\phi_1 = (\frac{\tau_1 \tau_M}{\tau_1 (1 - \frac{1}{\Omega_M}) - \tau_M}) \ln(\frac{\tau_1 (1 - \frac{1}{\Omega_M})}{\tau_M}),$$

5 where "ln" represents the logarithm to the base e, the natural logarithm.

For ϕ_2 , an analysis almost identical to equations 20 through 27 above is derived. The differences are two-fold. First, a biphasic waveform reverses the flow of current through the myocardium during ϕ_2 . Reversing the flow of current in the circuit model changes the sign on the current. The sign changes on the right hand side of equation 23.

The second difference is the step taken to incorporate an independent ϕ_2 into the charge burping model. Therefore, the ϕ_2 ODE incorporates the C_2 capacitor set and their associated leading-edge voltage, $V_{2'}$ for the ϕ_2 portion of the pulse. Then τ_2 represents the ϕ_2 time constant; $\tau_2 = RC_2$, and $V_S = -V_2 e^{-t/\tau_2}$. Equation 23 now becomes:

(29)
$$\frac{dV_{M}}{dt} + (\frac{V_{M}}{\tau_{M}}) (1 - \frac{1}{\Omega_{M}}) = \frac{-V_{2}e^{-t/\tau_{2}}}{\tau_{M}\Omega_{S}}.$$

Equation 29 is again a first-order linear ODE. In a similar manner, 20 its general solution is determined to be:

(30)

$$V_{M2}(t) = k e^{(-t/\tau_M)(1 - \frac{1}{\Omega_M})} - (\frac{V_2}{\Omega_S})(\frac{\tau_2}{\tau_2(1 - \frac{1}{\Omega_M}) - \tau_M}).$$

To determine the constant of integration k, the value of V_{M2} at the end of ϕ_1 is

5 (31)
$$V_{M2}(0) = V_{M1}(d_{\phi 1}) = V_{\phi 1},$$

where $d_{\phi 1}$ is the overall time of discharge for ϕ_1 and $V_{\phi 1}$ is the voltage left on the cell at the end of ϕ_1 . Applying the initial condition to equation 30 and solving for k:

(32)
$$k = V_{\phi 1} + (\frac{V_2}{\Omega_S})(\frac{\tau_2}{\tau_2(1 - \frac{1}{\Omega_M}) - \tau_M}).$$

The solution to the initial-value problem for ϕ_2 is

(33)
$$V_{M2}(t) = (\frac{V_2}{\Omega_S})(\frac{\tau_2}{\tau_2(1 - \frac{1}{\Omega_M}) - \tau_M})(e^{-(t/\tau_M)(1 - \frac{1}{\Omega_M})} - e^{-t/\tau_2})$$
$$-(t/\tau_M)(1 - \frac{1}{\Omega_M})$$
$$+ V_0 e^{-(t/\tau_M)(1 - \frac{1}{\Omega_M})}.$$

10

15

20

Equation 33 provides a means to calculate the residual membrane potential at the end of φ_2 for the cells that were not stimulated by $\varphi_1.$ Setting Equation 33 equal to zero, we solve for t, thereby determining the duration of φ_2 , denoted $d\varphi_2$, such that $V_{M2}(d\varphi_2)=0.$ By designing φ_2 with a duration $d\varphi_2$, the biphasic shock pulse removes the residual change placed on a cell by $\varphi_1.$ We determine d φ_2 to be:

(34)
$$d_{\phi 2} = \left(\frac{\tau_2 \tau_M}{\tau_2 (1 - \frac{1}{\Omega_M}) - \tau_M}\right) \cdot \ln\left(1 + \left(\frac{\tau_2 (1 - \frac{1}{\Omega_M}) - \tau_M}{\tau_2}\right) - \left(\frac{\Omega_S V_{\phi 1}}{V_2}\right)\right).$$

From the equations above, an optimal monophasic or biphasic defibrillation waveform may be calculated for an external defibrillator.

As an example, an external defibrillator may be designed as set forth below. Assume a monophasic truncated exponential shock pulse, a 200 μF capacitor, so that $\tau_1 = R \bullet (200~\mu F)$. Suppose also that the external defibrillator is designed to apply the maximal cardiac cell response design rule (equation 27C) to determine the duration of the discharge. Suppose further that the human cardiac cell time constant is estimated to be 3±1 ms. Further assume that the external defibrillator energy source comprises five 1000 μF capacitors in series to implement a 200 μF capacitor bank. If each capacitor is charged to 400V, for a total of 2000V for the leading-edge voltage, this represents 400J of stored energy. The transchest elements are

estimated at: 82% current through the thoracic cage; 14% through the chest wall and lungs in parallel; and 4% of applied current through the lung in series with the heart. Then the membrane resistance coefficient $\Omega_{\rm M}$ =5.9, and the system resistance coefficient $\Omega_{\rm S}$ =2.3. Then the table below illustrates the application of the design rule as the overall chest resistance ranges from 25 Ω to 200 Ω :

R (Ω)	τ_1	$d(\phi_1)$	V	${ m E}_{ m delivered}$
25	5.2	5.05	757	343
50	10.2	6.90	1017	297
75	15.2	8.15	1170	263
100	20.2	9.10	1275	238
125	25.2	9.90	1350	216
150	30.2	10.55	1410	201
175	35.2	11.15	1457	186
200	40.2	11.65	1497	176

It should be noted and understood that the design of ϕ_2 is independent from ϕ_1 . To design ϕ_2 , the only information necessary from ϕ_1 is where the cell response was left when ϕ_1 was truncated. Additionally, ϕ_2 need not use the same or similar circuitry to that used for ϕ_1 . For example, ϕ_2 may use a model as illustrated in Figure 5B where ϕ_1 may use the model illustrated in Figure 5A or vice versa.

15

10

DESCRIPTION OF THE PRESENT INVENTION

From Equations 27, 27C, 33, and 34 above it is evident that the characteristics of the cell membrane responses are functionally related to

15

20

25

30

the defibrillator time constants τ_1 and τ_2 , and to the time constant of the cell membrane τ_M . Time constants τ_1 and τ_2 are established by the capacitance of the capacitors C_1 and C_1 and the electrode system resistance R_s . It has been determined that efficacious and relatively low energy biphasic external defibrillation pulses can be generated from relatively low capacitance capacitors if the phase-duration ratio $(d_{\phi 2}/d_{\phi 1})$ is optimized to meet certain criteria described below.

Figure 6A is a graph of experimentally derived intra cardiac defibrillation thresholds (DFTs) as a function of biphasic defibrillation pulse phase-duration ratios for pulses generated from both $140\mu F$ and $40\mu F$ capacitors. The defibrillation threshold is statistically computed from the experimental data and is the defibrillation pulse energy at a 50% effective defibrillation dose. It is evident from Figure 6A that, with phase-duration ratios greater than one, efficacious biphasic defibrillation pulses having relatively low energy levels can be generated from $40\mu F$ capacitors. In comparison, similar biphasic defibrillation pulses having these phase-duration ratios and generated from $140\mu F$ capacitors required relatively high energy levels to achieve the same efficacy.

Figure 6B is a graph of experimentally derived intra cardiac defibrillation thresholds as a function of total pulse duration (i.e., both phases one and two) for pulses generated from both the $140\mu F$ and $40\mu F$ capacitors. From this figure it is evident that at the lowest defibrillation thresholds, the durations of biphasic defibrillation waveforms produced by both the $140\mu F$ and $40\mu F$ capacitors are similar. However, the intra cardiac biphasic defibrillation waveforms generated by the $140\mu F$ capacitor with the shorter total durations and small phase duration ratios have higher thresholds. Further, the intra cardiac biphasic defibrillation waveforms generated by the $140\mu F$ capacitor with the longer total durations and larger phase duration ratios have the highest defibrillation thresholds.

Figure 7 is a graph of optimal first and second phase pulse component durations ($d_{\phi 1}$ and $d_{\phi 2}$) and the optimal phase-duration ratio

WO 97/38754 PCT/US97/06003

5

10

15

- 26 -

 $(d_{\varphi 2}/d_{\varphi 1})$ as a function of both the capacitance of the capacitor used to generate the pulse component and the defibrillator time constant. The capacitance values on the graph are scaled to the pulse component durations and phase-duration ratios on the basis of a 50Ω defibrillator-patient resistance. The total duration of the defibrillation pulse is the sum of the first and second phase pulse components.

From the information represented in Figures 6A, 6B and 7, it has been determined that for a given pulse generation capacitor such as C_1 and C_2 having relatively small values (i.e., less than about $100\mu F$) and where τ_1 and τ_2 are less than τ_M , preferred biphasic external defibrillation waveforms will have a phase-duration ration $(d_{\phi 2}/d_{\phi 1})$ greater than one. Particularly efficacious external defibrillation waveforms meeting these requirements will be provided most preferably from pulse generation capacitors of less than about $60\mu F$. For the higher resistance patient the pulse generation capacitors may be less than $40\mu F$. Furthermore, particularly efficacious external defibrillation waveforms meeting these requirements will have a phase-duration ratio $(d_{\phi 2}/d_{\phi 1}) \ge 1.5$. The table below illustrates capacitor values for a range of resistance values.

P (0)	
R (Ω)	Cap (μF)
50	72
60	60
70	50
80	45
90	40
100	36
110	32
120	30
130	28
140	26
150	24

Each row entry represents the point marked * in Figure 7, for a fixed resistance value, and as determined from equations 27, 27C, 33 and 34. More than 90% of external defibrillation shocks are applied across a patient load from 60Ω to 90Ω , and thereby demonstrating that pulse generation capacitors of less than about $60\mu F$ are optimally suited for external defibrillation.

Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit or scope of the present invention.

WO 97/38754

What is claimed is:

11

12

13

14

15

16

1 1. An external defibrillator for delivering a truncated waveform 2 having a first waveform phase and a second waveform phase, the 3 defibrillator having a first charge storage component, a first truncating 4 switch connected in series with the first charge storage component, a 5 second charge storage component, a second truncating switch connected in 6 series with the second charge storage component, waveform control 7 circuitry connected to the first and second truncating switches for 8 independently operating the first and second truncating switches, and a 9 pair of electrodes connected across the first and second circuits, the 10 defibrillator comprising:

- 28 -

the waveform control circuitry controlling the first and second truncating switches such that the duration of the second phase waveform delivered by the second charge storage component is greater than the duration of the first phase waveform delivered by the first charge storage component.

- 1 2. The defibrillator of claim 1 wherein the duration of the 2 second phase waveform is at least fifty percent greater than the duration 3 of the first phase waveform.
- 1 3. The defibrillator of claim 1 wherein the duration of the second phase waveform is at least twice the duration of the first phase waveform.
- An external defibrillator for delivering a truncated damped sinusoidal waveform having a first waveform phase and a second waveform phase, the defibrillator having a first charge storage component, a first inductive component connected in series with the first charge storage component, a first truncating switch connected in series with the

defibrillator comprising:

14

15

16

17

18

19

20

first charge storage component and the first inductive component, a 6 7 second charge storage component, a second inductive component connected in series with the second charge storage component, a second 8 truncating switch connected in series with the second charge storage 9 component and the second inductive component, waveform control 10 circuitry connected to the first and second truncating switches for 11 12 independently operating the first and second truncating switches, and a pair of electrodes connected across the first and second circuits, the 13

the waveform control circuitry controlling the first and second truncating switches such that the duration of the second phase waveform delivered by the second charge storage component is greater than the duration of the first phase waveform delivered by the first charge storage component.

- 1 5. The defibrillator of claim 4 wherein the duration of the 2 second phase waveform is at least fifty percent greater than the duration 3 of the first phase waveform.
- 1 6. The defibrillator of claim 4 wherein the duration of the second phase waveform is at least twice the duration of the first phase waveform.
- 7. An external defibrillator for applying a truncated waveform having a first waveform phase and a second waveform phase to a pair of electrodes, the electrodes being in electrical communication with a patient, the patient having a certain cell membrane time constant, the external defibrillator having pulse generation capacitor means, the defibrillator comprising:
- 7 the pulse generation capacitor means being less than 100 μ F.


WO 97/38754 PCT/US97/06003


- 1 8. The external defibrillator of claim 7 wherein the pulse
- 2 generation capacitor means are less than 60 μ F.
- 1 9. The external defibrillator of claim 7 wherein the pulse
- 2 generation capacitor means are less than 40 μ F.
- 1 10. The external defibrillator of claim 7 wherein the pulse
- 2 generation capacitor means have a time constant, said time constant being
- 3 less than the patient cell membrane time constant.
- 1 11. An external defibrillator for applying a truncated waveform
- 2 having a first waveform phase and a second waveform phase to a pair of
- 3 electrodes, the electrodes being in electrical communication with a patient,
- 4 the patient having a certain cell membrane time constant, the external
- 5 defibrillator having pulse generation capacitor means, the defibrillator
- 6 comprising:
- 7 the pulse generation capacitor means having a first
- 8 capacitor and a second capacitor, the first capacitor being less
- 9 than 100 μ F and the second capacitor being less than 100 μ F.
- 1 12. The external defibrillator of claim 11 wherein the first
- 2 capacitor is less than 60 μ F and the second capacitor is less than 60 μ F.
- 1 13. The external defibrillator of claim 11 wherein the first
- 2 capacitor is less than 40 μ F and the second capacitor is less than 40 μ F.
- 1 14. The external defibrillator of claim 11 wherein the first
- 2 capacitor has a time constant, said time constant being less than the patient
- 3 cell membrane time constant, and wherein the second capacitor has a time
- 4 constant, said time constant being less than the patient cell membrane
- 5 time constant.


1	15. A method for externally defibrillating the heart of a patient					
2	having heart cell membranes characterized by a time constant $ au_{M'}$					
3	including:					
4	providing a defibrillation pulse application electrode					
5	system including a pair of electrodes and characterized by a					
6	resistance R _s and positioning the electrodes on the chest of a					
7	patient;					
8	providing a first capacitor set characterized by a					
9	capacitance C_1 <100µF where $R_sC_1 = \tau_s < \tau_M$, and charging the					
10	first capacitor set to a charge potential; and					
11	discharging the first capacitor set through the electrode					
12	system to provide a first phase component defibrillation					
13	pulse having a first polarity and a first duration.					
4						
1	16. The method of claim 15 wherein providing the first capacitor					
2	set includes providing a capacitor set characterized by a capacitance					
3	C_1 <60 μ F.					
1	17. The method of claim 15 wherein providing the first capacitor					
2	set includes providing a capacitor set characterized by a capacitance					
3	C_1 <40µF.					
1	18. The method of claim 15 further including:					
2	providing a second capacitor set characterized by a					
3	capacitance C_2 <100µF where $R_sC_2 = \tau_s$ < τ_M , and charging the					
4	second capacitor set to a charge potential; and					
5	discharging the second capacitor set through the					
6	electrode system after discharging the first capacitor set, to					
7	provide a second phase component defibrillation pulse					
8	having a second polarity and a second duration, wherein the					


- 9 second duration is a duration which is greater than the first duration.
- 1 19. The method of claim 18 wherein providing the first and
- 2 second capacitor sets includes providing first and second capacitor sets
- 3 characterized by capacitances C_1 and C_2 <60 μ F.
- 1 20. The method of claim 18 wherein providing the first and
- 2 second capacitor sets includes providing first and second capacitor sets
- 3 characterized by capacitances C_1 and C_2 <40 μ F.
- 1 21. The method of claim 18 wherein the second duration of the
- 2 second pulse component is at least about twice the first duration of the first
- 3 pulse component.
- 1 22. The method of claim 18 wherein the second duration of the
- 2 second pulse component is at least about 50% greater than the first
- 3 duration of the first pulse component.
- 1 23. The method of claim 18 wherein the second duration of the
- 2 second pulse component is greater than the first duration of the first pulse
- 3 component.
- 1 24. An external defibrillator for applying a damped sinusoidal
- 2 waveform having a first waveform phase and a second waveform phase to
- 3 a pair of electrodes, the electrodes being in electrical communication with
- 4 a patient, the patient having a certain cell membrane time constant, the
- 5 external defibrillator having pulse generation capacitor means, the
- 6 defibrillator comprising:
- 7 the pulse generation capacitor means being less than 100 μ F.


- 1 25. The external defibrillator of claim 24 wherein the pulse
- 2 generation capacitor means are less than 60 μ F.
- 1 26. The external defibrillator of claim 24 wherein the pulse
- 2 generation capacitor means are less than 40 μF .
- 1 27. The external defibrillator of claim 24 wherein the pulse
- 2 generation capacitor means have a time constant, said time constant being
- 3 less than the patient cell membrane time constant.
- 1 28. An external defibrillator for applying a damped sinusoidal
- 2 waveform having a first waveform phase and a second waveform phase to
- 3 a pair of electrodes, the electrodes being in electrical communication with
- 4 a patient, the patient having a certain cell membrane time constant, the
- 5 external defibrillator having pulse generation capacitor means, the
- 6 defibrillator comprising:
- the pulse generation capacitor means having a first
- 8 capacitor and a second capacitor, the first capacitor being less
- 9 than 100 μF and the second capacitor being less than 100 μF .
- 1 29. The external defibrillator of claim 28 wherein the first
- 2 capacitor is less than 60 μF and the second capacitor is less than 60 μF .
- 1 30. The external defibrillator of claim 28 wherein the first
- 2 capacitor is less than 40 μ F and the second capacitor is less than 40 μ F.
- 1 31. The external defibrillator of claim 28 wherein the first
- 2 capacitor has a time constant, said time constant being less than the patient
- 3 cell membrane time constant, and wherein the second capacitor has a time
- 4 constant, said time constant being less than the patient cell membrane
- 5 time constant.
























SUBSTITUTE SHEET (RULE 26)



INTERNATIONAL SEARCH REPORT

International application No. PCT/US97/06003

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) :A61N 1/39 US CL :607/5 According to International Patent Classification (IPC) or to both national classification and IPC						
B. FIELDS SEARCHED						
Minimum documentation searched (lassification system follows	ed by classification sym	bols)			
U.S. : 607/4-8						
Documentation searched other than m	unimum documentation to the	e extent that such docum	nents are included	in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS						
C. DOCUMENTS CONSIDER	ED TO BE RELEVANT					
Category* Citation of documen	nt, with indication, where a	ppropriate, of the releva	int passages	Relevant to claim No.		
X US 5,385,575 document.	US 5,385,575 A (ADAMS) 31 January 1995, entire document.			7-14, 24-31		
A				15-23		
Y US 5,468,254 document.	US 5,468,254 A (HAHN et al) 21 November 1995, entire document.					
document.	A (GLINER et al)			1-6		
Further documents are listed in		. See patent	family annex.			
 Special categories of cited document "A" document defining the general state to be of particular relevance 		date and not in o	ublished after the inte onflict with the applica ry underlying the inve	mational filing date or priority tion but cited to understand the ention		
"E" cartier document published on or af	ter the international filing data	"X" document of par	rticular relevance; the	claimed invention cannot be		
"L" document which may throw doubts cited to establish the publication d	on priority claim/a) or which is	considered novel when the docum	or cannot be consider ent is taken alone	red to involve an inventive step		
special reason (as specified) O* document referring to an oral disclosure, use, exhibition or other means		"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art				
P document published prior to the inte the priority date claimed	_	er of the same patent				
Date of the actual completion of the i	Date of mailing of the international search report 0 3 SEP 1997					
Name and mailing address of the ISA Commissioner of Patents and Trademark Box PCT	Authorized officer Diane Smith for					
Washington, D.C. 20231 Facsimile No. (703) 305-3230	SCOTT GETZOW					
. uvoudde 140 1701) 107-4740	,	Telephone No. (70)	31 300 3007			